Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
Noosa News21 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business24 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News22 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business15 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today